Matrix type transdermal therapeutic system containing captopril: formulation optimization, in vitro and ex vivo...

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Materials Science

Background:

• Transdermal drug delivery offers a non-invasive route for systemic medication.
• Captopril, an angiotensin-converting enzyme inhibitor, requires effective delivery systems for chronic conditions.
• Developing stable and efficient transdermal therapeutic systems (TTS) for captopril is crucial for patient compliance and therapeutic outcomes.

Purpose of the Study:

• To develop and characterize novel transdermal therapeutic systems (TTS) for captopril delivery.
• To evaluate the in vitro release kinetics and ex vivo diffusion profiles of captopril from the developed TTS.
• To identify optimal formulations suitable for transdermal captopril administration.

Main Methods:

• Synthesis and characterization of transdermal therapeutic systems (TTS) using Eudragit RL 100 and RS 100 polymers.
• Assessment of formulation properties including appearance, thickness, and captopril content.
• In vitro drug release studies and ex vivo diffusion studies using Franz diffusion cells across synthetic membranes and human skin.

Main Results:

• Successfully developed transdermal therapeutic systems (TTS) containing captopril with controlled release characteristics.
• Diffusion profiles were influenced by membrane properties (thickness, pore size, hydrophilicity/hydrophobicity) and formulation composition.
• Formulations F15 and F16 demonstrated favorable release and diffusion behavior.

Conclusions:

• Transdermal therapeutic systems (TTS) containing captopril were successfully prepared using pH-independent Eudragit polymers.
• The study identified specific formulations (F15 and F16) as highly suitable for transdermal captopril delivery.
• This research contributes to the advancement of non-invasive drug delivery methods for antihypertensive agents.